| abstract |
Use of an immune response modifier (IRM) compound selected from the groupnconsisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fusedncycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-nand oxazolo-quinolineamines and pyridinamines, imidazonaphthyridine andntetrahydroimidazonaphthyridine amines in the manufacture of a pharmaceuticalnformulation for the treatment of cervical dysplasia, said formulation additionallyncomprising:n a fatty acid; a preservative system; and a carbomer. |